TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Today

Rule Breakers article.

TMFBiologyFool published an update. 1:15 AM

Rule Breakers article.

TMFBiologyFool published an update. 12:35 AM

Yesterday

NL

Article

TMFBiologyFool published an article 11:52 PM

Waiting for Profitability at Genomic Health, Inc.

The first quarter produced a loss, as expected, but the growth should set up Genomic Health for a fourth-quarter profit if reimbursement comes to fruition.

NL

Article

TMFBiologyFool published an article 5:46 PM

It's Partners and Pipeline Before Bean Counting at Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals highlights its new partnerships while continuing to shrug off sales of its approved drug, Kynamro.

Fri May 1

Rule Breakers article.

TMFBiologyFool published an update. 7:58 PM

Rule Breakers article.

TMFBiologyFool published an update. 7:39 PM

NL

Article

TMFBiologyFool published an article 7:37 PM

Gilead Sciences, Inc. Earnings: Hepatitis C Market by the Numbers

Gilead posts a solid quarter boosted by its hepatitis C franchise.

NL

Article

TMFBiologyFool published an article 2:49 PM

Waiting for Exelixis, Inc.'s Meteor to Land

Data from the biotech's kidney cancer trial won't be available until late in the second quarter or potentially even later.

NL

Article

TMFBiologyFool published an article 12:54 PM

Hot Issues on BioMarin Pharmaceutical Inc. Earnings Conference Call

Vimizim steals the show as investors wait for an FDA decision on drisapersen

Rule Breakers article.

TMFBiologyFool published an update. 3:02 AM

Income Investor article.

TMFBiologyFool published an update. 1:35 AM

Rule Breakers article.

TMFBiologyFool published an update. 1:27 AM

Thu Apr 30

NL

Article

TMFBiologyFool published an article 9:58 PM

Seattle Genetics, Inc. Posts Solid First-Quarter Revenue, Raises Expense Guidance

Not exactly the beat-and-raise investors were looking for.

NL

Article

TMFBiologyFool published an article 3:25 PM

Celgene Corporation Hits a Triple, Yet Investors Boo

Despite 20% revenue growth, high expectations hurt Celgene.

NL

Article

TMFBiologyFool published an article 1:47 PM

Teva Pharmaceutical Industries Ltd Posts Solid Quarter, Stays Mum on Mylan

Despite flat revenue, profits increased substantially.

Rule Breakers article.

TMFBiologyFool published an update. 2:12 AM

Rule Breakers article.

TMFBiologyFool published an update. 2:08 AM

Rule Breakers article.

TMFBiologyFool published an update. 1:59 AM

Wed Apr 29

NL

Article

TMFBiologyFool published an article 11:02 PM

Vertex Pharmaceuticals Incorporated: Waiting to Exhale

Earnings are important, but the approval of Orkambi towers over Vertex's long-term potential.

NL

Article

TMFBiologyFool published an article 9:31 PM

3 Things to Watch as BioMarin Pharmaceutical Inc. Reports Earnings

Focus will be on the potential approval of drisapersen, but don't forget about BioMarin's other drugs.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 96.06
Player Rank 2962 out of 75198
Score 1425.22
Score Change Today -5.64
Accuracy 67.31%
Active Picks 72
Total Picks 213
Best Pick MYL (+430.74)
Worst Pick INCY (-966.52)
Average Score per Pick 6.69
Charms Earned 11
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts